GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Singular Genomics Systems Inc (NAS:OMIC) » Definitions » Beneish M-Score

OMIC (Singular Genomics Systems) Beneish M-Score : -3.61 (As of Mar. 17, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Singular Genomics Systems Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.61 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Singular Genomics Systems's Beneish M-Score or its related term are showing as below:

OMIC' s Beneish M-Score Range Over the Past 10 Years
Min: -3.61   Med: -2.9   Max: -1.69
Current: -3.61

During the past 5 years, the highest Beneish M-Score of Singular Genomics Systems was -1.69. The lowest was -3.61. And the median was -2.90.


Singular Genomics Systems Beneish M-Score Historical Data

The historical data trend for Singular Genomics Systems's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Singular Genomics Systems Beneish M-Score Chart

Singular Genomics Systems Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
- - - - -1.69

Singular Genomics Systems Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -1.69 -2.96 -2.83 -3.61

Competitive Comparison of Singular Genomics Systems's Beneish M-Score

For the Medical Instruments & Supplies subindustry, Singular Genomics Systems's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Singular Genomics Systems's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Singular Genomics Systems's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Singular Genomics Systems's Beneish M-Score falls into.



Singular Genomics Systems Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Singular Genomics Systems for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.2954+0.528 * 0.0948+0.404 * 1.3947+0.892 * 1.0274+0.115 * 0.8325
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8831+4.679 * -0.031578-0.327 * 1.1271
=-3.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Total Receivables was $1.01 Mil.
Revenue was 0.406 + 0.737 + 0.442 + 1.081 = $2.67 Mil.
Gross Profit was -0.301 + -0.178 + -0.419 + -0.457 = $-1.36 Mil.
Total Current Assets was $129.81 Mil.
Total Assets was $186.55 Mil.
Property, Plant and Equipment(Net PPE) was $55.07 Mil.
Depreciation, Depletion and Amortization(DDA) was $6.85 Mil.
Selling, General, & Admin. Expense(SGA) was $48.17 Mil.
Total Current Liabilities was $17.61 Mil.
Long-Term Debt & Capital Lease Obligation was $45.02 Mil.
Net Income was -16.795 + -21.254 + -25.024 + -23.249 = $-86.32 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = $0.00 Mil.
Cash Flow from Operations was -19.788 + -18.038 + -23.703 + -18.902 = $-80.43 Mil.
Total Receivables was $3.33 Mil.
Revenue was 0.462 + 0.505 + 0.863 + 0.765 = $2.60 Mil.
Gross Profit was -0.065 + -0.092 + 0.056 + -0.024 = $-0.13 Mil.
Total Current Assets was $210.80 Mil.
Total Assets was $284.52 Mil.
Property, Plant and Equipment(Net PPE) was $71.90 Mil.
Depreciation, Depletion and Amortization(DDA) was $7.29 Mil.
Selling, General, & Admin. Expense(SGA) was $53.09 Mil.
Total Current Liabilities was $15.45 Mil.
Long-Term Debt & Capital Lease Obligation was $69.30 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1.011 / 2.666) / (3.331 / 2.595)
=0.37922 / 1.283622
=0.2954

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(-0.125 / 2.595) / (-1.355 / 2.666)
=-0.04817 / -0.508252
=0.0948

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (129.81 + 55.074) / 186.551) / (1 - (210.795 + 71.9) / 284.518)
=0.008936 / 0.006407
=1.3947

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=2.666 / 2.595
=1.0274

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(7.29 / (7.29 + 71.9)) / (6.847 / (6.847 + 55.074))
=0.092057 / 0.110576
=0.8325

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(48.169 / 2.666) / (53.091 / 2.595)
=18.067892 / 20.45896
=0.8831

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((45.023 + 17.609) / 186.551) / ((69.299 + 15.453) / 284.518)
=0.335737 / 0.297879
=1.1271

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-86.322 - 0 - -80.431) / 186.551
=-0.031578

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Singular Genomics Systems has a M-score of -3.61 suggests that the company is unlikely to be a manipulator.


Singular Genomics Systems Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Singular Genomics Systems's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Singular Genomics Systems Business Description

Traded in Other Exchanges
N/A
Address
3010 Science Park Road, San Diego, CA, USA, 92121
Singular Genomics Systems Inc is a life science technology company that is leveraging novel next generation sequencing and multiomics technologies to build products that empower researchers and clinicians. The product development pipeline comprises two initial integrated solutions, each designed to leverage Sequencing Engine and purpose built to address different applications. The G4 Sequencing Platform is designed to target the NGS market. The PX Integrated Solution is designed to target the single cell, spatial analysis and proteomics markets. Both integrated solutions are used in many different and diverse market segments, including basic biology, oncology, immunology, neurology, genetic diseases, infectious diseases, the human microbiome and many others.
Executives
Andrew Spaventa director, 10 percent owner, officer: Chief Executive Officer 10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Eli N. Glezer officer: Chief Scientific Officer 10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Jyotsna Ghai officer: Chief Operating Officer 3010 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Kim P. Kamdar director C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Marcia Eisenberg director C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Sam Ropp officer: Chief Commercial Officer 3010 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Michael J Pellini director 222 DUTTON MILL RD, WILLISTOWN PA 19380
Elaine R Mardis director 301 MERRITT 7, NORWALK CT 06851
James E Flynn 10 percent owner, other: *Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
David Daly officer: President and Chief Operating 10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Vincent Brancaccio officer: Vice President, HR 10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Dalen Meeter officer: Vice President, Finance 10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Daralyn Durie officer: General Counsel 10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Jorge Velarde officer: Senior Vice President 10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
David L Barker director 9885 TOWNE CENTRE DR, SAN DIEGO CA 92121